Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 1.00 |
| ▸ | HTR1D | P28221 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 4/20 | 1.00 |
| ▸ | HTR5A | P47898 | 4/20 | 1.00 |
| ▸ | HTR1E | P28566 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR1F | P30939 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389149 | 1.00 | HTR6 (1.00) | HTR6HTR1DHTR1AHTR7HTR5A | |
| Maleic Acid SCHEMBL5761324 | 0.90 | HTR6 (0.80) | HTR6HTR1DHTR1AHTR7HTR5A | |
| Fumaric Acid SCHEMBL5761326 | 0.90 | HTR6 (0.80) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL5766124 | 0.83 | HTR6 (1.00) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL29633021 | 0.83 | HTR6 (1.00) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL8691195 | 0.83 | HTR6 (0.71) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL5313708 | 0.81 | HTR6 (0.67) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL4656461 | 0.81 | HTR6 (0.70) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL9200463 | 0.79 | HTR6 (0.75) | HTR6HTR1DHTR1AHTR7HTR5A | |
| SCHEMBL29423321 | 0.78 | HTR6 (1.00) | HTR6HTR1DHTR1AHTR7HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| EP-4358943-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| WO-2022269266-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| WO-2022269264-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| EP-1149078-B1 | SELECTIVE 5-HT 6 RECEPTOR LIGANDS | UNIV VIRGINIA COMMONWEALTH (US) | 2006-03-08 | — | — | EP | claimed |
| EP-4358943-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022269266-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022269264-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | disclosed |
| EP-3027613-B1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIV JAGIELLONSKI (PL) | 2018-03-28 | — | — | EP | disclosed |
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIVERSITE DE MONTPELLIER (FR) | 2017-08-24 | — | — | US | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020103383-A1 | Selective 5-HT6 receptor ligands | GLENNON RICHARD A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103382-A1 | Selective 5-HT6 receptor ligands | GLENNON RICHARD A (US) | 2002-08-01 | — | — | US | disclosed |
| US-6403808-B1 | TREATING MENTAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-06-11 | — | — | US | disclosed |
| EP-1149078-A1 | SELECTIVE 5-HT 6? RECEPTOR LIGANDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000034242-A1 | SELECTIVE 5-HT6 RECEPTOR LIGANDS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103382-A1 | Selective 5-HT6 receptor ligands | HTR6, HTR4, HTR5A | HTR6 1/4885HTR1D 16/4885HTR1A 4/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885HTR1D 19/4885HTR1A 8/4885 |
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | HTR6, HTR2C, HTR3B | HTR6 1/4885HTR1D 54/4885HTR1A 15/4885 |
| US-20020103383-A1 | Selective 5-HT6 receptor ligands | HTR6, HTR4, HTR5A | HTR6 1/4885HTR1D 16/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.